99-22099. Psychopharmacologic Drugs Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 64, Number 165 (Thursday, August 26, 1999)]
    [Notices]
    [Page 46687]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-22099]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Psychopharmacologic Drugs Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION:  Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). The meeting will 
    be open to the public.
        Name of Committee: Psychopharmacologic Drugs Advisory Committee.
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA's regulatory issues.
        Date and Time: The meeting will be held October 7, 1999, from 8:30 
    a.m. to 5 p.m., and October 8, 1999 from 8 a.m. to 4:30 p.m.
        Location:  Holiday Inn, Versailles Ballrooms I and II, 8120 
    Wisconsin Ave., Bethesda, MD.
        Contact Person: Sandra L. Titus, Center for Drug Evaluation and 
    Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for 
    express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 
    301-827-7001, or by e-mail at tituss@cder.fda.gov'', or FDA Advisory 
    Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
    Washington, DC area) code 12544. Please call the Information Line for 
    up-to-date information on this meeting.
        Agenda: On October 7, 1999, the committee will consider the safety 
    and efficacy of new drug application (NDA) supplement 20-592/S-009, 
    Zyprexa (olanzapine, Lilly), proposed to treat psychosis 
    associated with dementia. On October 8, 1999, the committee will 
    consider the safety and efficacy of NDA supplement 19-839/S-026, 
    Zoloft (sertraline hydrochloride, Pfizer Pharmaceuticals) 
    proposed to treat posttraumatic stress disorder.
        Procedure: Interested persons may present data, information, or 
    views, orally or in writing, on issues pending before the committee. 
    Written submissions may be made to the contact person by October 1, 
    1999. Oral presentations from the public will be scheduled between 
    approximately 1 p.m. and 2 p.m. on both days. Time allotted for each 
    presentation may be limited. Those desiring to make formal oral 
    presentations should notify the contact person before October 1, 1999, 
    and submit a brief statement of the general nature of the evidence or 
    arguments they wish to present, the names and addresses of proposed 
    participants, and an indication of the approximate time requested to 
    make their presentation.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: August 18, 1999.
    Linda A. Suydam,
    Senior Associate Commissioner.
    [FR Doc. 99-22099 Filed 8-25-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
08/26/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-22099
Pages:
46687-46687 (1 pages)
PDF File:
99-22099.pdf